Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DCTH Delcath Systems	$16.19 -1.3%	$13.20	$6.33 ▼ $18.23	$563.83M	0.72	374,630 shs	524,173 shs
LMAT LeMaitre Vascular	$81.01 -2.0%	$84.02	$71.42 ▼ $109.58	$1.83B	0.86	167,572 shs	165,768 shs
NVCR NovoCure	$19.37 +1.0%	$17.51	$14.17 ▼ $34.13	$2.16B	0.73	1.14 million shs	873,347 shs
WRBY Warby Parker	$20.10 -2.4%	$17.01	$12.46 ▼ $28.68	$2.10B	2.01	1.91 million shs	1.89 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DCTH Delcath Systems	-1.34%	-6.09%	+34.92%	+16.35%	+120.27%
LMAT LeMaitre Vascular	-2.02%	-0.60%	-11.50%	-18.92%	+1.05%
NVCR NovoCure	+0.99%	+9.13%	+5.79%	+0.73%	-13.22%
WRBY Warby Parker	-2.05%	+0.09%	+29.93%	-17.30%	+17.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DCTH Delcath Systems	3.6003 of 5 stars	3.5	5.0	0.0	0.0	3.9	2.5	0.6
LMAT LeMaitre Vascular	2.8009 of 5 stars	2.3	1.0	4.2	0.0	3.0	2.5	1.3
NVCR NovoCure	3.7962 of 5 stars	3.3	2.0	0.0	4.5	3.4	1.7	0.0
WRBY Warby Parker	2.9615 of 5 stars	3.3	2.0	0.0	0.0	3.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DCTH Delcath Systems	3.00	Buy	$24.00	48.24% Upside
LMAT LeMaitre Vascular	2.63	Moderate Buy	$98.14	21.15% Upside
NVCR NovoCure	2.67	Moderate Buy	$32.83	69.51% Upside
WRBY Warby Parker	2.61	Moderate Buy	$22.56	12.25% Upside

Current Analyst Ratings Breakdown

Latest DCTH, WRBY, NVCR, and LMAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $29.00
5/22/2025	WRBY Warby Parker	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $21.00
5/21/2025	WRBY Warby Parker	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	WRBY Warby Parker	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	WRBY Warby Parker	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$17.00 ➝ $22.00
5/21/2025	WRBY Warby Parker	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$18.00 ➝ $21.00
5/21/2025	WRBY Warby Parker	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $24.00
5/13/2025	WRBY Warby Parker	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$23.00 ➝ $20.00
5/9/2025	WRBY Warby Parker	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $20.00
5/9/2025	WRBY Warby Parker	Telsey Advisory Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $22.00
5/1/2025	WRBY Warby Parker	Telsey Advisory Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DCTH Delcath Systems	$53.85M	10.47	N/A	N/A	$0.72 per share	22.49
LMAT LeMaitre Vascular	$226.26M	8.09	$1.43 per share	56.52	$13.38 per share	6.05
NVCR NovoCure	$621.71M	3.47	N/A	N/A	$3.39 per share	5.71
WRBY Warby Parker	$795.09M	2.64	N/A	N/A	$3.08 per share	6.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DCTH Delcath Systems	-$47.68M	-$0.50	N/A	N/A	N/A	-150.70%	-338.16%	-104.02%	8/4/2025 (Estimated)
LMAT LeMaitre Vascular	$30.10M	$1.98	44.27	37.33	2.22	19.40%	13.15%	11.47%	8/7/2025 (Estimated)
NVCR NovoCure	-$207.04M	-$1.51	N/A	N/A	N/A	-25.93%	-41.48%	-12.74%	7/24/2025 (Estimated)
WRBY Warby Parker	-$63.20M	-$0.12	N/A	201.00	N/A	-4.39%	-8.26%	-4.37%	8/14/2025 (Estimated)

Latest DCTH, WRBY, NVCR, and LMAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	DCTH Delcath Systems	$0.10	$0.03	-$0.07	$0.03	$16.83 million	$19.80 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million
3/6/2025	Q4 2024	DCTH Delcath Systems	-$0.10	-$0.11	-$0.01	-$0.11	$14.96 million	$15.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.99%	+13.30%	40.40%	14 Years
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
WRBY Warby Parker	N/A	N/A	N/A	N/A	N/A

Latest DCTH, WRBY, NVCR, and LMAT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DCTH Delcath Systems	N/A	1.34	1.03
LMAT LeMaitre Vascular	N/A	7.74	5.52
NVCR NovoCure	0.27	1.49	1.44
WRBY Warby Parker	N/A	2.47	2.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DCTH Delcath Systems	61.12%
LMAT LeMaitre Vascular	84.64%
NVCR NovoCure	84.61%
WRBY Warby Parker	93.24%

Insider Ownership

Company	Insider Ownership
DCTH Delcath Systems	17.40%
LMAT LeMaitre Vascular	9.50%
NVCR NovoCure	6.29%
WRBY Warby Parker	26.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DCTH Delcath Systems	60	34.83 million	26.24 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.06 million	Optionable
NVCR NovoCure	1,320	111.49 million	101.40 million	Optionable
WRBY Warby Parker	3,030	104.50 million	74.67 million	Optionable

DCTH, WRBY, NVCR, and LMAT Headlines

Recent News About These Companies

Google Is Back to Smart Glasses: This Time It Might Work

May 28 at 2:16 PM | techopedia.com

Youngme E. Moon Sells 33,073 Shares of Warby Parker Inc. (NYSE:WRBY) Stock

May 28 at 4:49 AM | insidertrades.com

Warby Parker Inc. (NYSE:WRBY) Shares Acquired by Two Sigma Investments LP

May 28 at 4:09 AM | marketbeat.com

Loop Capital Maintains Buy Rating on Warby Parker (WRBY) Stock

May 27 at 4:12 PM | insidermonkey.com

Woodline Partners LP Sells 85,914 Shares of Warby Parker Inc. (NYSE:WRBY)

May 27 at 4:38 AM | marketbeat.com

Man Group plc Sells 18,862 Shares of Warby Parker Inc. (NYSE:WRBY)

May 27 at 3:53 AM | marketbeat.com

Warby Parker Inc. (NYSE:WRBY) Shares Sold by Millennium Management LLC

May 27 at 3:38 AM | marketbeat.com

Warby Parker FY2026 EPS Forecast Increased by Roth Capital

May 27 at 2:07 AM | marketbeat.com

Bank of America Corp DE Increases Position in Warby Parker Inc. (NYSE:WRBY)

May 26 at 3:21 AM | marketbeat.com

FY2026 EPS Estimate for Warby Parker Increased by Analyst

May 26 at 2:09 AM | americanbankingnews.com

Q3 Earnings Estimate for Warby Parker Issued By Roth Capital

May 25, 2025 | marketbeat.com

Q3 Earnings Forecast for Warby Parker Issued By Roth Capital

May 25, 2025 | americanbankingnews.com

Warby Parker (NYSE:WRBY) Price Target Raised to $21.00

May 24, 2025 | marketbeat.com

Castleark Management LLC Invests $4.29 Million in Warby Parker Inc. (NYSE:WRBY)

May 24, 2025 | marketbeat.com

Warby Parker (NYSE:WRBY) Stock Price Expected to Rise, TD Securities Analyst Says

May 24, 2025 | americanbankingnews.com

Warby Parker (WRBY) Joins AI Race, Google Backs Smart Glasses Project

May 23, 2025 | insidermonkey.com

Warby Parker (NYSE:WRBY) Sees Strong Trading Volume After Analyst Upgrade

May 23, 2025 | marketbeat.com

Warby Parker teams with Google. Is the stock a buy?

May 23, 2025 | cantechletter.com

Warby Parker (NYSE:WRBY) Price Target Raised to $24.00 at TD Securities

May 23, 2025 | marketbeat.com

13,688 Shares in Warby Parker Inc. (NYSE:WRBY) Bought by Gotham Asset Management LLC

May 23, 2025 | marketbeat.com

Citigroup Forecasts Strong Price Appreciation for Warby Parker (NYSE:WRBY) Stock

May 23, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH, WRBY, NVCR, and LMAT Company Descriptions

Delcath Systems NASDAQ:DCTH

$16.19 -0.22 (-1.34%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$16.18 -0.01 (-0.03%)

As of 05/28/2025 06:17 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

LeMaitre Vascular NASDAQ:LMAT

$81.01 -1.67 (-2.02%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$81.02 +0.01 (+0.01%)

As of 05/28/2025 04:10 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure NASDAQ:NVCR

$19.37 +0.19 (+0.99%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$19.65 +0.28 (+1.44%)

As of 05/28/2025 07:57 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Warby Parker NYSE:WRBY

$20.10 -0.49 (-2.38%)

Closing price 05/28/2025 03:59 PM Eastern

Extended Trading

$20.48 +0.38 (+1.89%)

As of 05/28/2025 07:55 PM Eastern

Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time